Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
gptkb:Injection
Nasal spray |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1945 |
| gptkbp:boosterRecommended |
No
|
| gptkbp:broadcastOn |
Annually
|
| gptkbp:canBeGivenWith |
vaccine
Pneumococcal vaccine |
| gptkbp:category |
Inactivated vaccine
Live attenuated vaccine |
| gptkbp:contains |
Hemagglutinin antigen
Inactivated influenza virus Live attenuated influenza virus Neuraminidase antigen |
| gptkbp:contraindication |
History of Guillain-Barré syndrome
Severe egg allergy |
| gptkbp:cost |
Varies by country
|
| gptkbp:developedBy |
gptkb:Jonas_Salk
gptkb:Thomas_Francis_Jr. |
| gptkbp:distribution |
Global
|
| gptkbp:effect |
Varies by season
|
| https://www.w3.org/2000/01/rdf-schema#label |
Influenza Vaccine
|
| gptkbp:prevention |
gptkb:Influenza
|
| gptkbp:producedBy |
gptkb:Sanofi_Pasteur
gptkb:AstraZeneca gptkb:Seqirus GlaxoSmithKline |
| gptkbp:publicHealthConcern |
Reduces influenza-related deaths
Reduces influenza-related hospitalizations |
| gptkbp:recommendation |
Children
Elderly Pregnant women Healthcare workers |
| gptkbp:relatedGroup |
People with chronic diseases
Immunocompromised individuals |
| gptkbp:routeOfAdministration |
Intramuscular
Intranasal |
| gptkbp:sideEffect |
Fever
Muscle aches Soreness at injection site |
| gptkbp:storage |
2-8°C
|
| gptkbp:type |
Quadrivalent
Trivalent |
| gptkbp:updated |
Annually by WHO recommendations
|
| gptkbp:usedIn |
Pandemic influenza response
Seasonal influenza prevention |
| gptkbp:WHOStatus |
gptkb:Essential_Medicines
|
| gptkbp:bfsParent |
gptkb:Immunization_Clinic
|
| gptkbp:bfsLayer |
5
|